Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye

Abstract

The present invention relates to compositions comprising a proanthocyanidin, as well as methods for using such compositions in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis(eczema), allergic contact dermatitis, seborrheic dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye. The present invention also relates to compositions comprising a proanthocyanidin, glycyrrhetinic acid and telmesteine, as well as methods for using such compositions in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, radiation dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory condition of mucosae and of an inflammatory condition in the eye.

1 - 24 . (canceled)  
   
   
       25 . A composition comprising 
 (i) a compound which reduces the concentration of elastase, collagenase, hyaluronidase and beta glucuronidase;    (ii) an anti-inflammatory agent; and    (iii) either or each of an anti-mycolytic agent and inhibitor of elastase and collagenase.    
   
   
       26 . The composition of  claim 25 , wherein said compound that compound which reduces the concentration of elastase, collagenase, hyaluronidase and beta glucuronidase is a proanthocyanadin.  
   
   
       27 . The composition of  claim 25 , wherein said anti-inflammatory agent is glycerrhetinic acid.  
   
   
       28 . The composition of  claim 25 , wherein said anti-mycolytic agent and inhibitor of elastase and collagenase is telmesteine.  
   
   
       29 . The composition of  claim 25 , further comprising an ingredient selected from the group consisting of an antibacterial agent, a disinfectant, an antifungal agent, an analgesic agent, an anti-inflammatory agent, an emollient and a local anaesthetic agent.  
   
   
       30 . The composition of  claim 25 , wherein said composition is in the form of a cream, a gel, a suspension, a spray or an ointment.  
   
   
       31 . The composition of  claim 25 , wherein said composition is in an admixture with a pharmaceutically acceptable carrier rich in polyunsaturated fatty acids.  
   
   
       32 . The composition of  claim 25 , wherein said pharmaceutically acceptable carrier comprises a a carrier selected from the group consisting of squalene, karite butter, ocyl plamitate and oenthera oil.  
   
   
       33 . The composition of  claim 25 , wherein said pharmaceutically acceptable carrier is karite butter.  
   
   
       34 . The composition of  claim 25 , wherein said composition contains and antioxidant agent.  
   
   
       35 . The composition of  claim 34 , wherein said antioxidant is a tocopherol, ascorbic acid, esters thereof and combinations of tocopherol, ascorbic acid and esters thereof.  
   
   
       36 . The composition of  claim 25 , wherein said composition further comprises an anti-inflammatory agent selected from he group consisting of salicylic acid, hyaluronic acid, alpha-bisabolol, zinc picolate, allantoin, a steroid, a corticosteroid, a vitamin D analog, a retinoid and piroctone olamine, or combinations thereof.  
   
   
       37 . A method for the treatment or prevention of an inflammatory condition of the mucosae, skin or eye comprising administering topically a composition according to claim  1  in an amount effective to treat said condition.  
   
   
       38 . The method of  claim 37 , wherein said condition is selected from the group consisting of dermatitis conditions and skin impairments such as atopic dermatitis, contact dermatitis, allergic contact dermatitis, allergic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis of hands or feet, generalized exfoliative dermatitis, stasis dermatitis, neonatal dermatitis, pediatric dermatitis, localized scratch dermatitis, toxic/irritating contact eczema, allergic contact eczema, type I or type IV photoallergic contact eczema, contact urticaria, dyshidrosiform eczema, age-caused wrinkles, sun damage itching, psoriasis vulgaris, flaking eczema, psoriasis pustulosa, psoriasis arthropatica, psoriatic erythroderma, rosacea, photodermatosis, radiodermatitis acuta and chronica (UV and ionizing radiation therapy), chronic actinic dermatitis, photouticaria (uticaria solaris), polymorphic photodermatosis, prurigo (strophulus, uticaria papulosa), subacuta, chronica, acne vulgaris, juvenile and adult (acne with comedones, papulous, pustulous, nodose, i.e., nodular, nodulocystic acne), acne conglobata (special form: hidradenitis suppurativa), acne fulminans, acne tetrad, acne neonatorum, senile acne, mechanical acne forms (excoriated acne), acne cosmetica, folliculitis with superinfected acne (Staphylococci), occupation-related acne forms (for example chlorine acne), decubitis, ulcus cruris, deficient ipoactive skin, localized scratch dermatitis rinophyma, ichthyosis, xerosis, and perioral dermatits.  
   
   
       39 . The method of  claim 37 , wherein said composition is co-administered with a second compositions to treat or prevent said inflammatory condition of the mucosae, skin, or eye.  
   
   
       40 . The method of  claim 39 , wherein said second composition is selected from a group consisting of an emollient, a salicylic acid, coal tar, an anthralin, a steroid, a corticosteroid, a vitamin D analog and a retinoid.  
   
   
       41 . The method of  claim 39 , wherein said second composition is in the same composition as the composition of claim  1 .  
   
   
       42 . The method of  claim 39 , wherein said second composition is in a separate composition as the composition of claim  1 .  
   
   
       43 . The method of  claim 37 , wherein said administration is vaginal, rectal, buccal or in the eye.